JP2021507690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021507690A5 JP2021507690A5 JP2020530653A JP2020530653A JP2021507690A5 JP 2021507690 A5 JP2021507690 A5 JP 2021507690A5 JP 2020530653 A JP2020530653 A JP 2020530653A JP 2020530653 A JP2020530653 A JP 2020530653A JP 2021507690 A5 JP2021507690 A5 JP 2021507690A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- arthritis
- juvenile
- disease
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 83
- 201000001981 dermatomyositis Diseases 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 206010003246 arthritis Diseases 0.000 claims 16
- 230000000366 juvenile effect Effects 0.000 claims 12
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 10
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 10
- 201000004681 Psoriasis Diseases 0.000 claims 10
- 208000002574 reactive arthritis Diseases 0.000 claims 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 208000034189 Sclerosis Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 206010003267 Arthritis reactive Diseases 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 206010047115 Vasculitis Diseases 0.000 claims 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 201000004384 Alopecia Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000004232 Enteritis Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000033464 Reiter syndrome Diseases 0.000 claims 4
- 231100000360 alopecia Toxicity 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 4
- 210000003979 eosinophil Anatomy 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000005987 polymyositis Diseases 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 210000002435 tendon Anatomy 0.000 claims 4
- 230000001256 tonic effect Effects 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000012657 Atopic disease Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000003807 Graves Disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010028372 Muscular weakness Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010030216 Oesophagitis Diseases 0.000 claims 2
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 206010061481 Renal injury Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 208000006881 esophagitis Diseases 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 230000001434 glomerular Effects 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000037806 kidney injury Diseases 0.000 claims 2
- 208000002741 leukoplakia Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 2
- 231100000855 membranous nephropathy Toxicity 0.000 claims 2
- 230000036473 myasthenia Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 208000012102 polyarticular juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 2
- 230000001185 psoriatic effect Effects 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 230000000552 rheumatic effect Effects 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 230000002269 spontaneous effect Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595357P | 2017-12-06 | 2017-12-06 | |
| US62/595,357 | 2017-12-06 | ||
| US201862675972P | 2018-05-24 | 2018-05-24 | |
| US62/675,972 | 2018-05-24 | ||
| US201862721644P | 2018-08-23 | 2018-08-23 | |
| US16/109,875 | 2018-08-23 | ||
| US62/721,644 | 2018-08-23 | ||
| US16/109,897 | 2018-08-23 | ||
| US16/109,875 US10174091B1 (en) | 2017-12-06 | 2018-08-23 | IL-2 muteins |
| US16/109,897 US10174092B1 (en) | 2017-12-06 | 2018-08-23 | IL-2 muteins |
| PCT/US2018/062808 WO2019112854A1 (en) | 2017-12-06 | 2018-11-28 | Il-2 muteins and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021507690A JP2021507690A (ja) | 2021-02-25 |
| JP2021507690A5 true JP2021507690A5 (enExample) | 2022-01-06 |
| JP7250790B2 JP7250790B2 (ja) | 2023-04-03 |
Family
ID=66751187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530653A Active JP7250790B2 (ja) | 2017-12-06 | 2018-11-28 | Ｉｌ－２ムテインおよびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3720470A4 (enExample) |
| JP (1) | JP7250790B2 (enExample) |
| KR (3) | KR102687035B1 (enExample) |
| CN (2) | CN118515780A (enExample) |
| AU (2) | AU2018378078B2 (enExample) |
| BR (1) | BR112020011343A2 (enExample) |
| CA (1) | CA3083941A1 (enExample) |
| IL (1) | IL274844A (enExample) |
| MX (1) | MX2020005208A (enExample) |
| SG (1) | SG11202003965VA (enExample) |
| WO (1) | WO2019112854A1 (enExample) |
| ZA (1) | ZA202003386B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3720871A4 (en) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| CN114728179A (zh) * | 2019-08-19 | 2022-07-08 | 潘迪恩运营公司 | 利用pd-1激动剂的靶向免疫耐受 |
| CN110642934B (zh) * | 2019-09-10 | 2022-08-23 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
| WO2021076805A1 (en) | 2019-10-15 | 2021-04-22 | Moderna TX, Inc. | Mrnas encoding immune modulating polypeptides and uses thereof |
| TW202136317A (zh) | 2019-12-20 | 2021-10-01 | 美商再生元醫藥公司 | 新穎之ｉｌ２促效劑及其使用方法（二） |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| CN112358540A (zh) * | 2020-11-03 | 2021-02-12 | 安徽环球基因科技有限公司 | 一种重组il2在毕赤酵母中的生产方法 |
| MX2023006599A (es) | 2020-12-04 | 2023-06-19 | Visterra Inc | Metodos de uso de agentes de interleucina-2. |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| TWI859752B (zh) * | 2022-03-03 | 2024-10-21 | 大陸商海南先聲藥業有限公司 | IL2突變體-抗體Fc嵌段融合蛋白的藥物組合物及其應用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1007907B (zh) * | 1985-04-30 | 1990-05-09 | 弗·哈夫曼-拉罗彻有限公司 | 重组人类白细胞介素-2的提纯 |
| WO2005007121A2 (en) * | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| JP6093712B2 (ja) * | 2010-12-22 | 2017-03-08 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン２のスーパーアゴニストおよびアンタゴニスト |
| US20140170153A1 (en) * | 2011-05-31 | 2014-06-19 | Novo Nordisk A/S | Il-21 epitope and il-21 ligands |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| MX378790B (es) * | 2014-07-21 | 2025-03-10 | Delinia Inc | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
| CN109071623B (zh) * | 2016-05-04 | 2022-05-27 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| EP3606947B1 (en) * | 2017-04-03 | 2022-12-21 | F. Hoffmann-La Roche AG | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
| AU2018273914A1 (en) * | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| EP3720871A4 (en) * | 2017-12-06 | 2021-09-15 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US20220041713A1 (en) * | 2018-09-18 | 2022-02-10 | Pandion Operations, Inc | Targeted immunotolerance |
-
2018
- 2018-11-28 BR BR112020011343-3A patent/BR112020011343A2/pt unknown
- 2018-11-28 JP JP2020530653A patent/JP7250790B2/ja active Active
- 2018-11-28 CN CN202410591221.4A patent/CN118515780A/zh active Pending
- 2018-11-28 MX MX2020005208A patent/MX2020005208A/es unknown
- 2018-11-28 EP EP18887098.4A patent/EP3720470A4/en active Pending
- 2018-11-28 WO PCT/US2018/062808 patent/WO2019112854A1/en not_active Ceased
- 2018-11-28 SG SG11202003965VA patent/SG11202003965VA/en unknown
- 2018-11-28 CN CN201880077653.6A patent/CN111432831B/zh active Active
- 2018-11-28 KR KR1020207017255A patent/KR102687035B1/ko active Active
- 2018-11-28 CA CA3083941A patent/CA3083941A1/en active Pending
- 2018-11-28 KR KR1020247023942A patent/KR20240115352A/ko active Pending
- 2018-11-28 AU AU2018378078A patent/AU2018378078B2/en active Active
- 2018-11-28 KR KR1020247008135A patent/KR102684426B1/ko active Active
-
2020
- 2020-05-21 IL IL274844A patent/IL274844A/en unknown
- 2020-06-05 ZA ZA2020/03386A patent/ZA202003386B/en unknown
-
2024
- 2024-08-29 AU AU2024216451A patent/AU2024216451A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021507690A5 (enExample) | ||
| CN106211782B (zh) | 抗体-fynomer缀合物 | |
| ES2822431T3 (es) | Polipéptidos de unión a IL-17A | |
| ES2823563T3 (es) | Polipéptidos de unión específica novedosos y usos de los mismos | |
| JP2012516158A5 (enExample) | ||
| JP2019503167A5 (enExample) | ||
| EA035973B9 (en) | Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same | |
| JP2019058197A5 (enExample) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| JP2011528332A5 (enExample) | ||
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| JP2015518479A5 (enExample) | ||
| JP2011526792A5 (enExample) | ||
| JP2023052258A5 (enExample) | ||
| JPWO2012026309A1 (ja) | 抗ｐａｄ４抗体医薬の創成 | |
| EP2091968A2 (en) | Il-21 variants | |
| JP2014531417A (ja) | シクロスポリン誘導体 | |
| JPH10257893A5 (enExample) | ||
| JP2016520620A5 (enExample) | ||
| JP2020513020A5 (enExample) | ||
| TWI429451B (zh) | 對具有ｅｌｒ－ｃｘｃ趨化素高度親和力的受體蛋白細胞所引發疾病之拮抗治療劑 | |
| CN117843803B (zh) | 串联单域抗体及其在疾病治疗中的应用 | |
| WO2017162208A1 (zh) | 靶向pd-1的多肽及其应用 | |
| JP2009542235A5 (enExample) | ||
| Sridharan et al. | Tail wags the dog: activity of krait natriuretic peptide is determined by its C-terminal tail in a natriuretic peptide receptor-independent manner |